Protease

Paritaprevir View larger

Paritaprevir

AOB37526

CAS: 1216941-48-8

 

Chemical Name: ABT-450; (2R,6S,12Z,13aS,14aR,16aS)-N-(Cyclopropylsulfonyl)-6-(5-methylpyrazin-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16atetradecahydrocyclopropa(E)pyrrolo(1,2-a)(1,4)diazacyclopentadecine-14a(5H)-carboxamide

More details

Molarity Calculation Cart®

HOW TO ORDER

$37.00

$37.00 per mg

Quantity Discount Table - Order More To Get More Price Discount

QuantitymgUnit Price ($/mg or $/Unit)Final Price
1100 $16.65 Total: $1,665.00
150 $19.24 Total: $962.00
125 $22.57 Total: $564.25
110 $26.64 Total: $266.40
15 $31.45 Total: $157.25

Data sheet

Molecular FormulaC40H43N7O7S
Molecular Weight765.88
CAS Numbers1216941-48-8
Storage Condition0°C (short term), -20°C (long term), desiccated
SolubilityDMSO
Purity98% by HPLC
SynonymATB450; ABT-450; ABT 450; Paritaprevir; Veruprevir; Brand name: VIEKIRA PAK
IUPAC/Chemical Name(2R,6S,13aS,14aR,16aS,Z)-N-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide
InChl KeyUAUIUKWPKRJZJV-QPLHLKROSA-N
InChl CodeInChI=1S/C40H43N7O7S/c1-24-21-42-33(22-41-24)35(48)43-32-16-6-4-2-3-5-11-25-20-40(25,39(51)46-55(52,53)27-17-18-27)45-36(49)34-19-26(23-47(34)38(32)50)54-37-30-14-8-7-12-28(30)29-13-9-10-15-31(29)44-37/h5,7-15,21-22,25-27,32,34H,2-4,6,16-20,23H2,1H3,(H,43,48)(H,45,49)(H,46,51)/b11-5-/t25-,26-,32+,34+,40-/m1/s1
SMILES CodeO=C([C@]([C@]1([H])/C=CCCCCC[C@@H]2NC(C3=NC=C(C)N=C3)=O)(C1)NC([C@@](C[C@@H](OC4=C5C=CC=CC5=C(C=CC=C6)C6=N4)C7)([H])N7C2=O)=O)NS(=O)(C8CC8)=O
References1) Minaei AA, Kowdley KV. ABT-450/ ritonavir and ABT-267 in combination with ABT-333 for the treatment of hepatitis C virus. Expert Opin Pharmacother. 2015 Apr;16(6):929-37. doi: 10.1517/14656566.2015.1024653. Review. PubMed PMID: 25800085.

2) Gamal N, Vitale G, Andreone P. ABT-450: a novel agent for the treatment of CHC genotype 1: focus on treatment-experienced patients. Expert Rev Anti Infect Ther. 2015 Mar;13(3):295-304. doi: 10.1586/14787210.2015.1001746. Review. PubMed PMID: 25582226.

More info

Hepatitis C Virus NS3/4A Protease Inhibitor, also acting as a potential inhibitor of SARS-CoV-2 3CLpro